The influence of high serum testosterone levels on the long-term prognosis in male patients undergoing hepatectomy for early stage hepatocellular carcinoma without vascular invasion

World Journal of Surgery

Volumn 31, Issue 7, 2007, Pages 1469-1473

  Lin, Min Che ^a   Wu, Cheng Chung ^a,b,c   Cheng, Shao Bin ^a,c   Liu, Tse Jia ^a   P'eng, Fang Ku ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADULT; ARTICLE; BLOOD VESSEL INJURY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; PROGNOSIS; RISK; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TESTOSTERONE;

EID: 34250658470     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-007-9094-3     Document Type: Article

References (41)

1. Peters RI. (1976) Pathology of hepatocellular carcinoma. In Okuda K, Peters RI, editors, Hepatocellular Carcinoma, New York, John Wiley & Sons:107-168
2. Editorial. (1987) Hepatocellular cancer: differences between high and low incidence regions. Lancet 2:1183-1184
3. Yu MW, Tsai SF, Hsu KH, et al. (1988) Epidemiological characteristics of malignant neoplasm in Taiwan. II. Liver cancer. J Natl Public Health Assoc 8:125-138
4. Yu MW, Chen CJ. (1993) Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 53:790-794
5. Yu MW, Cheng SW, Lin MW, et al. (2000) Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 92:2023-2028
6. Yu MW, Yang YC, Yang SY, et al. (2001) Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 93:1644-1651
7. Tanaka K, Sakai H, Hashizume M, et al. (2000) Serum testosterone: estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 60:5106-5110
8. Sobin LH, Wittekind CH. (2002) International Union Against Cancer. TNM Classification of Malignant Tumors, 6th Edition, John Wiley, New York
9. Couinaud C. (1989) Surgical Anatomy of the Liver, Revisited. C. Couinaud, Paris
10. Wu CC, Ho WL, Yeh DC, et al. (1996) Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? Surgery 120:34-39
11. Wu CC, Yeh DC, Lin MC, et al. (2001) Improving operative safety for cirrhotic liver resection. Br J Surg 88:210-215
12. Wu CC, Hwang CR, Liu TJ et al. (1996) Effects and limitations of prolonged ischemia for hepatic resection of the cirrhotic liver. Br J Surg 83:121-124
13. Wu CC, Yeh DC, Ho WM, et al. (2002) Occlusion of hepatic blood inflow for complex central liver resections in cirrhotic patients. Arch Surg 137:1369-1376
14. Nagasue N, Galizia G, Yukaya H, et al. (1989) Better survival in women than in men after radical resection of hepatocellular carcinoma. Hepatogastroenterology 36:379-383
15. Lee CC, Chau GY, Lui WY, et al. (2000) Better post-resectional survival in female cirrhotic patients with hepatocellular carcinoma. Hepatogastroenterology 47:446-449
16. Lam CM, Yong JL, Chan AO, et al. (2005) Better survival in female patients with hepatocellular carcinoma: oral contraceptive pills related? J Clin Gastroenterol 39:533-539
17. Morris HP, Firminger HI. (1960) Influence of sex and sex hormones on development of hepatomas and other hepatic lesions in strain AX C rats ingesting 2-diacetylaminofluorene. J Natl Cancer Inst 16:927-949
18. Firminger HI, Reuber MD. (1961) Influence of adrenocortical, androgenic, and anabolic hormones on the development of carcinoma and cirrhosis of the liver in A x C rats fed N-2-fluorenyldicetamide. J Natl Cancer Inst 27:559-595
19. Toh YC. (1981) Effect of neonatal castration on liver tumor induction by N-2-fluorenylacetamide in suckling BALB/c mice. Carcinogenesis 2:1219-1221
20. Moore MR, Drinkwater NR, Miller EC, et al. (1981) Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine. Cancer Res 41:1585-1593
21. Matsuura B, Taniguchi Y, Ohta Y. (1994) Effect of antiandrogen treatment on chemical hepatocarcinogenesis in rats. J Hepatol 21:187-193
22. Johnson FL, Lerner KG, Siegel M, et al. (1972) Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 2:1273-1276
23. Farrell GC, Joshua DE, Uren RF, et al. (1975) Androgen-induced hepatoma. Lancet 1:430-432
24. Mokrohisky ST, Ambruso DR, Hathaway WE. (1977) Fulminant hepatic neoplasia after androgen therapy. N Engl J Med 296:1411-1412
25. Johnson PJ. (1984) Sex hormones and the liver. Clin Sci (Lond) 66:369-376
26. Ho WL, Wu CC, Yeh -D-C, et al. (2002) Roles of the glucocorticoid receptor in resectable hepatocellular carcinoma. Surgery 131:19-25
27. Eagon PK, Porter LE, Francavilla A, et al. (1985) Estrogen and androgen receptors in liver: their role in liver disease and regeneration. Semin Liver Dis 5:59-69
28. Yu L, Nagasue N, Makino Y, et al. (1995) Effect of androgens and their manipulation on cell growth and androgen receptor (AR) levels in AR-positive and -negative human hepatocellular carcinomas. J Hepatol 22:295-302
29. Nagasue N, Ito A, Yukaya H, et al. (1985) Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 89:643-647
30. Nagasue N, Chang YC, Hayashi T, et al. (1989) Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. Ann Surg 209:424-427
31. Nagasue N, Yu L, Yukaya H, et al. (1995) Androgen and estrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg 82:542-547
32. Imamura H, Matsuyama Y, Tanaka E, et al. (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol 38:200-207
33. Shah SA, Greig PD, Gallinger S, et al. (2006) Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 202:275-283
34. Sakon M, Umeshita K, Nagano H, et al. (2000) Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 135:1456-1459
35. Ohnishi S, Murakami T, Moriyama T, et al. (1986) Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology 6:440-443
36. Boix L, Castells A, Bruix J, et al. (1995) Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. J Hepatol 22:616-622
37. Forbes A, Wilkinson ML, Iqbal MJ, et al. (1987) Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone. Eur J Cancer Clin Oncol 23:1659-1664
38. Gupta S, Korula J. (1988) Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. J Clin Gastroenterol 10:651-654
39. Guechot J, Peigney N, Ballet F, et al. (1989) Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. Hepatology 1989;10:346-348
40. Chao Y, Chan WK, Huang YS, et al. (1996) Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer 77:635-639
41. Pignata S, Daniele B, Gallo C, et al. (1998) Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit? Eur J Cancer 34:25-32